Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Carcinoma; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd; Eisai Inc

    • Most Recent Events

    • 19 Oct 2021 Results (n=152; data cutoff date December 12, 2019) assessing efficacy and safety of lenvatinib 18 mg versus 24 mg in patients with radioiodine refractory differentiated thyroid cancer, published in the Journal of Clinical Endocrinology and Metabolism.
    • 21 Sep 2021 Results assessing impact of lenvatinib treatment on HRQoL, presented at the 46th European Society for Medical Oncology Congress.
    • 11 Jan 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top